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Abstract
Background: Existing studies indicate a significant genetic component for sudden cardiac arrest (SCA) and genome-wide
association studies (GWAS) provide an unbiased approach for identification of novel genes. We performed a GWAS to
identify genetic determinants of SCA.
Methodology/Principal Findings: We used a case-control design within the ongoing Oregon Sudden Unexpected Death
Study (Oregon-SUDS). Cases (n=424) were SCAs with coronary artery disease (CAD) among residents of Portland, OR (2002–
07, population ,1,000,000) and controls (n=226) were residents with CAD, but no history of SCA. All subjects were of
White-European ancestry and GWAS was performed using Affymetrix 500K/5.0 and 6.0 arrays. High signal markers were
genotyped in SCA cases (n=521) identified from the Atherosclerosis Risk in Communities Study (ARIC) and the
Cardiovascular Health Study (CHS) (combined n=19,611). No SNPs reached genome-wide significance (p,5610
28). SNPs at
6 loci were prioritized for follow-up primarily based on significance of p,10
24 and proximity to a known gene (CSMD2,
GPR37L1, LIN9, B4GALNT3, GPC5, and ZNF592). The minor allele of GPC5 (GLYPICAN 5, rs3864180) was associated with a lower
risk of SCA in Oregon-SUDS, an effect that was also observed in ARIC/CHS whites (p,0.05) and blacks (p,0.04). In a
combined Cox proportional hazards model analysis that adjusted for race, the minor allele exhibited a hazard ratio of 0.85
(95% CI 0.74 to 0.98; p,0.01).
Conclusions/Significance: A novel genetic locus for SCA, GPC5, was identified from Oregon-SUDS and successfully validated
in the ARIC and CHS cohorts. Three other members of the Glypican family have been previously implicated in human
disease, including cardiac conditions. The mechanism of this specific association requires further study.
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Sudden cardiac arrest (SCA) claims 250,000–300,000 lives in the
US and 4–5 million around the world, on an annual basis [1].
Despite 60 years of significant advancements in rapid emergency
response systems and resuscitation methodology in the developed
world, the current average rate of survival from SCA in North
America is less than five percent [2]. Therefore, the development of
effective risk stratification and primary prevention approaches is
especially relevant for this significant and global public health issue.
Risk stratification for SCA is an area of active investigation, but
available techniques do not identify the vast majority of subjects at
risk [3]. Further advancements in this field await the discovery of
novel mechanisms related to ventricular arrhythmogenesis. Since
two community-based studies confirmed the significant genetic
contribution to occurrence of SCA [4,5], there is increasing
recognition of the fact that discovery of novel genetic variants
could lead to new mechanistic pathways. The availability of
genome-wide genotype data provides the opportunity to conduct a
comprehensive and unbiased survey of genetic determinants that
could influence the phenotype [6,7,8]. Previously, we successfully
used a GWAS to identify novel determinants of the QT interval.
These variants in NOS1AP were subsequently tested and found to
be associated with risk for SCA in the general population [9]. An
alternative approach is to directly test genetic variants for
association with SCA, which is the methodology employed in
the current study. The Oregon Sudden Unexpected Death Study
(Oregon-SUDS) is an ongoing, prospective, community-based
evaluation of approximately one million residents of the Portland,
Oregon metropolitan area [10]. Using a case-control approach we
performed a GWAS to identify genetic determinants of SCA.
Results were validated in two existing large population-based
cohorts, the Atherosclerosis Risk in Communities study (ARIC)
[11] and the Cardiovascular Health Study (CHS) [12].
Materials and Methods
Thisstudywasconducted accordingtotheprinciplesexpressedin
the Declaration of Helsinki. The study was approved the
Institutional Review Boards of Oregon Health and Science
University, Legacy Health Systems, VA Medical Center, Kaiser
Permanente NW, Portland OR; Southwest Washington Medical
Center, Vancouver, WA; The Johns Hopkins University School of
Medicine, Baltimore MD; Wake Forest University, Winston-Salem
NC; University of Texas Health Science Center at Houston, TX;
University of Washington, Seattle, WA; Group Health, Seattle,
WA,USA.Written informedconsentwasobtainedfrom allenrolled
subjects. If subjects were deceased at the time of ascertainment (i.e.
following a sudden cardiac death) consent was waived by the
respective Institutional Review Boards on grounds of scientific
feasibility. These latter subjects were de-identified for the purpose of
analysis, in conformation with procedures approved by the
respective Institutional Review Boards.
Overall Study Design
The GWAS was performed on a population-based group of
SCA cases and a group of control subjects, both with coronary
artery disease (Oregon-SUDS). Additional genotyping of SNPs
identified in the GWAS was performed in ARIC and CHS
(combined n=21,680, median follow-up ,14 yrs).
Study Populations
The Oregon-SUDS. Subjects included in the original GWAS
analysis were identified from the ongoing Oregon-SUDS, a
population-based study of SCA in the Portland, Oregon
metropolitan region (pop. approx. 1,000,000). Methods for this
study have been described previously [3,10,13]. Briefly, patients
with likely out of hospital SCA were referred from the regional
emergency medical response system (EMS), the County Medical
Examiner, and emergency departments of the 16 area hospitals.
SCA was defined as a sudden unexpected pulse-less condition of
likely cardiac origin; survivors of SCA were included. If un-
witnessed, SCAs were included if subjects were found dead within
24 hours of having last been seen alive and in normal state of
health. Subjects were excluded if they had a chronic terminal
illness (e.g. terminal cancer), or an identifiable non-cardiac
etiology of sudden death related to trauma, overdose, drowning
or suicide. For all cases of presumed SCA, three study physicians
performed in-house adjudication of SCA cases based on the arrest
circumstances, medical records and available autopsy data.
Cases included in the GWAS study were white non-Hispanic
SCA cases with DNA available (a blood or tissue sample was
available in 59% of cases). Case subjects were also required to have
documented significant coronary artery disease (CAD), or, if aged
$50 years, were assumed to have CAD (based on 95% likelihood
of CAD in SCA cases aged $50 years) [14,15]. Documented
significant CAD was defined as $50% stenosis of a major
coronary artery from an angiogram prior to arrest or at autopsy;
physician report of past MI; history of percutaneous coronary
intervention (PCI) or coronary artery bypass grafting (CABG);
autopsy-identified CAD; or MI by clinical data with any two of the
following three: ischemic symptoms, positive troponins or CKMB;
or convincing pathologic Q waves on ECG.
During the same time period a control group of subjects from
the same geographic region were identified who had definite CAD
(as defined above) after review of their medical records, but no
history of SCA.
ARIC/CHS
The ARIC study and CHS are population-based prospective
cohort studies of cardiovascular disease. The ARIC Study includes
15,792 persons aged 45–64 years at baseline (1987–89), randomly
chosen from four US communities [16]. ARIC cohort members
completed four clinic examinations, conducted approximately three
years apart between 1987 and 1998. CHS includes 5,888
participants.65 years ofageidentifiedfrom four U.S. communities
using Medicare eligibility lists. The original cohort included 5201
participants recruited in 1989–1990 and 687 additional subjects
were recruited in 1992–1993 to enhance the racial/ethnic diversity
of the cohort [17]. Clinic examinations for both ARIC and CHS
participants included assessment of cardiovascular risk factors, self-
reported medical family history, employment and educational
status, diet, physical activity, co-morbidities, and clinical and
laboratory measurements. The following exclusion criteria were
applied to obtain the final sample for the present analysis: poor
quality DNA (samples with ,50% of genotypes called), and self-
described ethnicity other than White or Black. For ARIC samples,
for which a substantial subset has Affymetrix 6.0 genotype data, we
excludedsampleswhosegenotypesdidnotmatchpreviousgenotype
data, genetic outliers identified using EIGENSTRAT [18], and first
degree relatives [19]. After these exclusions,19,611 individuals were
available for analysis.
Assessment of SCA has been previously described [9]. Briefly,
all cases of fatal CHD that occurred by July 31, 2002 in CHS and
December 31, 2002 in ARIC were reviewed and adjudicated by a
committee of physicians. SCA was operationally defined as a
sudden pulseless condition from a cardiac origin in a previously
stable individual, and the reviewers classified each CHD death as
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death, definite non-sudden death, or unclassifiable. The primary
outcome of SCA described in the present study combines both
definite and possible sudden arrhythmic death. For the present
analysis, participants were censored at time of loss to follow up or
death if the cause of death was other than SCA. For 91 cases, SCA
status could not be determined.
GWAS Genotyping and Quality Control
A total of 759 subjects (483 cases, 276 controls) were run on
GWAS platforms: 131 cases and 111 controls on the Affymetrix
500K array; 164 cases and 165 controls on the Affymetrix 5.0array;
and 188 cases on the Affymetrix 6.0 array. For the 500K platform,
genotypes were called using BRLMM [20], with a quality score
setting of 0.3. The 500K platform is run on 2 arrays, each with
,250,000 SNPs, and we required $88% complete data on each
array (11 samples failed). For the 5.0 and 6.0 platforms, which
genotype ,500,000 and ,900,000 SNPs on a single chip,
respectively, genotypes were called using Birdseed [21] with a
qualityscore setting of 0.1, and we required $95% complete data (1
sample failed). We removed samples for the following criteria: 1)
accidental duplicates (4 samples); 2) first degree relatives (1 sample);
3) discordant phenotypic and genotypic sex (9 samples); 4) samples
showing too much genetic sharing with all samples (likely
contaminated DNA) (4 samples); 5) genetic outliers identified using
EIGENSTRAT [18] with a setting of 5 iterations and 6 SD in the
top 3 eigenvectors (33 samples). Note that some samples failed more
than one QC check. The final dataset consisted of 700 samples (446
cases, 254 controls). We further restricted samples to those #80
years of age, to more closely match the cases and controls and
potentially enrich for a genetic component to SCA risk, yielding a
final dataset of 650 samples (424 cases and 226 controls).
Merging GWAS Data and Imputation
Monomorphic SNPs and SNPs with no genotypes calls (100%
missing) were removed from each dataset (500K, 5.0, 6.0). First,
the 500K and 5.0 datasets were merged, and subsequently all
SNPs with .10% missing data and/or Hardy-Weinberg equilib-
rium (HWE) P,0.00001 were removed from the 500K/5.0
dataset (final n=436,267 SNPs), and the 6.0 dataset (final
n=902,958 SNPs), and these 2 datasets were merged. Imputation
to fill in missing data was performed on the combined dataset
using MACH v1.16, with 50 rounds and 200 states [22]. SNPs that
were significantly different between cases genotyped on the 500K/
5.0 platforms and 6.0 platforms (n=14) and SNPs with minor
allele frequency ,0.01 were removed, and an additional round of
imputation was performed using the HapMap CEU dataset (r21a)
as a reference to generate genotype data on all Phase II HapMap
SNPs (n=2,557,332).
Quality Control for GWAS SNPs
Using QQ plots to identify classes of SNPs showing inflated
results, and thus a high likelihood of false-positives, we excluded
SNPs with low imputation quality (rsq ,0.85), MAF ,0.02, HWE
.0.001, and any SNP flagged by MACH as having a significantly
different allele frequency between the dataset and the reference
HapMap data. These criteria yielded 1,966,233 SNPs for analysis
withagenomiccontrolinflationfactorof1.015,showingnoevidence
for population stratification or inflated results due to imputation.
Validation Genotyping
Genotyping was performed using iPlex single base primer
extension with MALDI-TOF mass spectrometry according to
manufacturer protocols (Sequenom Inc., San Diego, CA). PCR
and extension primer sequences are available upon request.
Statistical Analyses
Analyses of the GWAS data were performed in PLINK [23],
using logistic regression adjusting for age and sex under an
additive genetic model. In ARIC/CHS, all analyses were stratified
by self-reported ethnicity. Because the study protocols were similar
across ARIC and CHS, the number of SCA events was modest
within each study, and initial genotype-phenotype analyses
indicated that the associations did not differ between the two
studies, all analyses were pooled across the two studies to increase
statistical power. The rare allele of each SNP in whites was
designated as the minor allele. Deviations from Hardy-Weinberg
proportions were assessed using the chi-squared goodness of fit test
within each ethnicity group. For SCA risk, single SNP genotype-
based analyses were performed. To estimate the relative hazards
and the significance of the association between each SNP genotype
and SCA risk while adjusting for covariates, Cox proportional
hazards models were constructed, and a Bonferroni-corrected-
alpha of 0.0125 (0.05/4) was used to declare statistical significance
in the age, sex, and study adjusted analysis. An additive model was
assumed for each SNP. For significant SNPs, a model assuming 3
genotypic risks was also constructed to confirm the use of the
additive model. The proportional hazards assumption was
checked with Schoenfeld’s residual [24]. As exploratory analyses,
the role of genotypic effects across various high-risk subgroups was
examined both with stratified analyses and by fitting interaction
terms into the regression models. Analyses were performed in R
(version 2.6.2).
Results
Baseline characteristics of subjects in the Oregon-SUDS
Case (n=424) and control (n=226) subjects in the Oregon-
SUDS GWAS were both predominantly male (72.9% vs. 68.6%,
p=0.25), while case subjects were younger than controls
(59.4612.3 vs. 63.269.9 yrs, p,0.0001); 75% of cases and 90%
of controls were age 50 or older (p,0.0001). All subjects included
in the Oregon-SUDS GWAS were white, based on inclusion
criteria. Risk factors for heart disease were common among both
cases and controls (diabetes mellitus was diagnosed in 29% cases
and 34% controls, p=0.25; obesity in 45% cases vs. 42% controls,
p=0.41. Among all SCD cases age $50, 58% of women and 63%
of men had documented significant CAD. Fifteen percent of cases
age $50 had an autopsy performed; in this subset, 85% of women
and 86% of men had significant CAD noted at autopsy. While a
history of prior cardiac events was relatively common among case
subjects (22% with prior MI; 22% with prior revascularization), a
history of prior cardiac arrest was uncommon (4 case subjects; 1%
of case population).
Oregon-SUDS GWAS
Since Oregon-SUDS samples were assayed across multiple
Affymetrix platforms, we performed several rounds of data
cleaning (of both samples and SNPs) as well as imputation of
non-genotyped SNPs, ultimately yielding 650 samples and ,2
million SNPs for analysis (see Methods). We performed a logistic
regression, adjusting for age and sex, and the genomic control
factor (l) was 1.002, showing no evidence for population
stratification or inflated results due to imputation. No SNPs met
genome-wide significance (P,5610
28, Figure 1, Table 1), and
thus we prioritized SNPs for follow-up based on the following
criteria: 1) significance (p,10
24); 2) multiple adjacent SNPs
Novel Locus for Sudden Death
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9879Figure 1. Summary of GWAS results from the Oregon-SUDS population. Chromosome is on the X-axis and the negative log of the P value is
on the Y-axis. Regions meeting criteria for follow-up in ARIC/CHS are highlighted in green.
doi:10.1371/journal.pone.0009879.g001
Table 1. Top results from the Oregon-SUDS GWAS.
SNP CHR Position MAF Rsq OR P GENE P*
rs16835611 1 33,710,878 0.18 1.0000 0.59 9.00E-05 CSMD2 0.02
rs7516762 1 198,824,237 0.11 0.9983 2.35 9.38E-05 GPR37L1 0.34
rs2306119 1 222,727,457 0.39 0.9952 0.61 5.60E-05 LIN9 0.08
rs7313849 12 481,855 0.09 0.8512 0.44 6.25E-05 B4GALNT3 0.15
rs3864180 13 91,234,489 0.39 0.9723 0.61 8.20E-05 GPC5 0.06
rs1429445 15 83,085,569 0.09 0.9335 3.08 2.11E-05 ZNF592 0.24
CHR=chromosome; MAF=minor allele frequency; Rsq=measure of imputation quality from MACH [22]; OR=odds ratio;
P*=P value comparing Oregon-SUDS controls to controls from the Wellcome Trust Case Control Consortium.
doi:10.1371/journal.pone.0009879.t001
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to genotyping artifacts); 3) within 25 kb of a known gene; and 4)
minor allele frequencies among controls not significantly different
(P,0.01) when compared to additional controls obtained from the
Wellcome Trust Case Control Consortium (WTCCC) data. This
final criterion was implemented to remove SNPs for which
associations appeared to be driven by the controls rather than the
cases, suggesting that imputation was of poor quality.
Six SNPs met these criteria (Table 1, Figure 1), and were
selected for validation in the combined ARIC and CHS cohorts.
Validation in ARIC/CHS
Of the six candidate SNPs from the Oregon-SUDS GWAS, one
failed assay design, and 1 was out of Hardy Weinberg equilibrium
(HWE) (P,0.001) in both whites and blacks from the ARIC/CHS
cohort. This SNP was also missing .5% data, suggesting poor
genotyping, and thus was subsequently dropped from all analyses.
Of the remaining 4 SNPs, all were in HWE (P.0.01) in whites and
blacks, with the exception of rs7313849 in blacks (P,0.0004), and
all had ,5% missing data.
In our final combined ARIC/CHS dataset after data cleaning
(see Methods), 521/19,520 individuals experienced SCA over a
median follow-up time of 13.5 years (14.1 in ARIC and 12.2 in
CHS). We performed Cox proportional hazards models for each
SNP, adjusting for age and sex, with time to SCA or loss to follow-
up as the outcome variable. Only rs3864180, an intronic SNP, was
significantly associated with SCA, and this association was
observed in both whites (P,0.05) and blacks (P,0.039)
(Table 2). In a combined analysis of both whites and blacks, we
observed a relative risk of 0.85 (95% CI, 0.74–0.98, P,0.01), after
adjusting for age, sex, and race/ethnicity (Figure 2). Additional
analyses were conducted to examine the impact of other CVD risk
factors on the association of rs3864180 with SCA. In the
combined racial cohort, we observed a statistically significant
stronger effect in ARIC (0.78) vs. CHS (0.94), as well as a stronger
effect in women (0.72) than in men (0.94) (Table S1). No other risk
factors showed a statistically significant interaction (P,0.05) with
the SNP, though we did observe stronger effects for those without
previous MI, age younger than 70 years, and the absence of
diabetes at baseline.
Association of rs3864180 with QT interval
We performed linear regression analysis on QT interval
adjusted for age, sex, heart rate, race/ethnicity and study site
(Table 3) and observed a decrease of 0.4760.18 ms in the QT
interval with the allele associated with reduced risk of SCA
(P,0.012). Further, we saw a statistically significant interaction
between rs3864180 and sex (P,0.012), with a stronger effect in
women, which was also seen in the association with SCA; although
not statistically significant, the effect on QT interval was observed
separately for both ARIC and CHS, and for both blacks and
whites. No significant difference was observed between ARIC and
CHS samples. Exclusion of all SCA cases did not significantly
change these results (data not shown).
Discussion
In this case-control study, we found that the minor allele of
rs3864180 (SNP in GPC5) conferred protection against SCA
among subjects recruited in the Oregon-SUDS. Furthermore, this
effect was validated among white and black subjects recruited in
the ARIC and CHS cohorts. In a Cox proportional hazards model
combining whites and blacks, adjusted for baseline age, sex, and
race, the risk ratio for the minor allele was 0.85 (95% CI 0.74 to
0.98; p,0.01).
Given that SCA is known to have a genetic component, the
identification of genetic variants that modulate risk can contribute
to an improved understanding of mechanisms. CAD is the disease
condition most commonly associated with SCA and is observed in
at least 80% of overall cases. Hence, our use of a population based
design in which all subjects had CAD increased the likelihood that
we would identify genetic variants that contribute specifically to
SCA among subjects with existing CAD. Prolongation of the QT
interval has been associated with increased SCA risk in the
community [13]. It is of interest that rs3864180 was also associated
with a small but significant effect on duration of the corrected QT
interval, with the protective allele associated with shorter QT
interval (P,0.012). For both SCA and QT interval, we observed a
significantly stronger effect in women. While these trends were not
significant, risk of SCA was higher in those without history of
previous MI, younger than 70 years of age, and no diabetes at
baseline. These findings are consistent with the expectation of
observing stronger genetic effects in individuals with fewer co-
morbidities. Since rs3864180 is a non-coding SNP, the possibility
exists that it is either in linkage disequilibrium with a coding SNP
or has a regulatory function.
The GPC5 gene encodes glypican 5, a member of the heparan
sulfate preoteoglycans (HSPGs) that are bound to the external
surface of the plasma membrane by glycosyl-phosphatidylinositol
(GPI) linkage [25]. There are six glypican family members in the
Human Genome (GPC1 to GPC6). While defects in GPC5 have
yet not been reported to be associated with disease, mutations in
three other members of the family have been associated with two
distinct syndromes. The Simpson-Golabi-Behmel syndrome
(SGBS) is a X-linked overgrowth/malformation syndrome caused
by mutations in GPC3 and GPC4 [26,27]. Cardiac arrhythmias
have been reported in patients with SGBS, likely contributing to
high incidence of death in early infancy and cardiac arrest in the
Table 2. Validation of top GWAS hits in combined ARIC and CHS cohorts, stratified by race/ethnicity.
Whites Blacks
SNP CHR Position GENE MAF RR SE P MAF RR SE P
rs16835611 1 33,710,878 CSMD2 0.16 0.93 0.11 0.25 0.03 0.94 0.31 0.42
rs7313849 12 481,855 B4GALNT3 0.12 0.96 0.11 0.37 0.43 0.99 0.11 0.48
rs3864180 13 91,234,489 GPC5 0.40 0.88 0.08 0.05 0.15 0.74 0.17 0.039
rs1429445 15 83,085,569 ZNF592 0.20 0.94 0.10 NS 0.05 1.03 0.24 0.45
NS indicates that the effect is in the opposite direction of Oregon-SUDS, P-values are one-sided. CHR=chromosome; MAF=minor allele frequency; RR=relative risk;
SE=standard error. Bold indicates significant association with SCA.
doi:10.1371/journal.pone.0009879.t002
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condition characterized by severe short stature and congenital
heart defects, caused by homozygosity for null mutations in GPC6
[29].
In the cardiovascular system, cell surfaces and surrounding
extracellular matrix express large quantities of HSPGs. These are
involved in regulating vasculogenesis and angiogenesis after
ischemic injury, interactions of cells with adhesive proteins and
blood vessels, proliferation of smooth muscle cells during
atherogenesis, metabolism of lipoproteins and non-thrombogenic
characteristics of endothelial cells [30]. A functional evaluation of
rs3864180 and other variations in the GPC5 gene is warranted.
There are several interesting possibilities for a role in the
pathobiology of SCA.
Several limitations should be considered with regard to
interpretation of our results. First, it is not known whether we
have identified the functional variant, or just a marker in LD with
the functional variant. Second, while rs3864180 is found within an
intron of GPC5, this does not definitively prove the involvement of
GPC5 in SCD risk, since it is possible for the functional variant
to act upon a more distant gene [31]. Finally, appropriate cau-
tion should be exercised in extrapolating these results to other
populations. It should be recognized that rs3864180 did not
reach genome-wide significance (P,5610
28) in either the original
GWAS or the validation study. Thus while validation of the
original GWAS finding in an independent population provides
evidence for a true association with lower SCD risk, additional
replication of these findings is warranted.
Conclusion
A novel, protective genetic locus for SCA, GPC5, was identified
from a large case-control study (Oregon-SUDS) and successfully
validated in the ARIC and CHS cohorts. The mechanism of this
association requires further study.
Supporting Information
Table S1 Protective effect of rs3864180 on risk of SCA in
ARIC/CHS stratified by risk factors for cardiovascular disease.
Found at: doi:10.1371/journal.pone.0009879.s001 (0.11 MB
DOC)
Table 3. Effect of rs3864180 on QT interval in ARIC/CHS.
Cohort N Beta SE P value P*
All 18,152 20.47 0.18 0.012
ARIC 13,587 20.36 0.21 0.09 NS
CHS 4,561 20.67 0.39 0.08
Blacks 4,229 21.04 0.57 0.07 NS
Whites 13,919 20.36 0.19 0.06
Women 10,306 20.72 0.27 0.007 0.012
Men 7,839 20.09 0.25 0.71
Beta is in ms. SE=standard error;
P* is the P value for the interaction term. Bold indicates significant association
for QT interval.
doi:10.1371/journal.pone.0009879.t003
Figure 2. Survival curves (free of sudden cardiac arrest) stratified by rs3864180 genotype in the combined ARIC/CHS cohort. Cox
proportional hazards model was adjusted for age, sex, and race/ethnicity. Individuals homozygous for the protective allele (GG) are shown in green,
heterozygotes (AG) in blue, and homozygous for the risk allele (AA) are in red.
doi:10.1371/journal.pone.0009879.g002
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